Inovio Pharmaceuticals, Inc. (INO) NASDAQ

1.21

-0.07(-5.47%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Jacqueline E. Shea	Chief Executive Officer, President & Director	889,099	1966
Peter D. Kies	Chief Financial Officer	598,278	1963
Michael Sumner	Chief Medical Officer & Head of Development	653,475	1965
Laurent Humeau	Chief Scientific Officer & Chairman of the Scientific Advisory Board	794,082	1967
Jeffrey Skolnik	Senior Vice President of Clinical Development	0	N/A
E. J. Brandreth	Senior Vice President of Quality Assurance	0	N/A
Robert J. Juba Jr.	Senior Vice President of Biological Manufacturing & Clinical Supply Management	0	N/A
Robert L. Crotty	General Counsel, Corporate Secretary & Chief Compliance Officer	0	1974
Shawn D. Bridy	Senior Vice President of Business Development	0	N/A
Jennie Willson	Director of Communications	0	N/A
Thomas Hong	Manager of Investor Relations	0	N/A

Name

Title

Pay

Year Born

Jacqueline E. Shea

Chief Executive Officer, President & Director

889,099

1966

Peter D. Kies

Chief Financial Officer

598,278

1963

Michael Sumner

Chief Medical Officer & Head of Development

653,475

1965

Laurent Humeau

Chief Scientific Officer & Chairman of the Scientific Advisory Board

794,082

1967

Jeffrey Skolnik

Senior Vice President of Clinical Development

N/A

E. J. Brandreth

Senior Vice President of Quality Assurance

N/A

Robert J. Juba Jr.

Senior Vice President of Biological Manufacturing & Clinical Supply Management

N/A

Robert L. Crotty

General Counsel, Corporate Secretary & Chief Compliance Officer

1974

Shawn D. Bridy

Senior Vice President of Business Development

N/A

Jennie Willson

Director of Communications

N/A

Thomas Hong

Manager of Investor Relations

N/A

Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.